Penumbra (PEN) Competitors $263.58 -9.16 (-3.36%) Closing price 09/15/2025 03:59 PM EasternExtended Trading$262.50 -1.07 (-0.41%) As of 09/15/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PEN vs. LNTH, ITGR, GEHC, PHG, ZBH, SNN, SOLV, STVN, IRTC, and BLCOShould you be buying Penumbra stock or one of its competitors? The main competitors of Penumbra include Lantheus (LNTH), Integer (ITGR), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), Solventum (SOLV), Stevanato Group (STVN), iRhythm Technologies (IRTC), and Bausch + Lomb (BLCO). These companies are all part of the "medical" sector. Penumbra vs. Its Competitors Lantheus Integer GE HealthCare Technologies Koninklijke Philips Zimmer Biomet Smith & Nephew SNATS Solventum Stevanato Group iRhythm Technologies Bausch + Lomb Lantheus (NASDAQ:LNTH) and Penumbra (NYSE:PEN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability. Which has more risk and volatility, LNTH or PEN? Lantheus has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Which has stronger earnings & valuation, LNTH or PEN? Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantheus$1.53B2.29$312.44M$3.7613.76Penumbra$1.19B8.60$14.01M$3.7670.10 Does the media favor LNTH or PEN? In the previous week, Lantheus had 47 more articles in the media than Penumbra. MarketBeat recorded 58 mentions for Lantheus and 11 mentions for Penumbra. Penumbra's average media sentiment score of 1.37 beat Lantheus' score of 0.35 indicating that Penumbra is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 13 Very Positive mention(s) 1 Positive mention(s) 36 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral Penumbra 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is LNTH or PEN more profitable? Lantheus has a net margin of 17.82% compared to Penumbra's net margin of 11.54%. Lantheus' return on equity of 34.06% beat Penumbra's return on equity.Company Net Margins Return on Equity Return on Assets Lantheus17.82% 34.06% 19.10% Penumbra 11.54%11.55%8.76% Do insiders and institutionals believe in LNTH or PEN? 99.1% of Lantheus shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 2.0% of Lantheus shares are held by insiders. Comparatively, 5.0% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer LNTH or PEN? Lantheus currently has a consensus target price of $89.67, suggesting a potential upside of 73.30%. Penumbra has a consensus target price of $302.93, suggesting a potential upside of 14.93%. Given Lantheus' higher probable upside, analysts plainly believe Lantheus is more favorable than Penumbra.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantheus 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Penumbra 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.88 SummaryLantheus and Penumbra tied by winning 8 of the 16 factors compared between the two stocks. Get Penumbra News Delivered to You Automatically Sign up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEN vs. The Competition Export to ExcelMetricPenumbraMED INSTRUMENTS IndustryMedical SectorNYSE ExchangeMarket Cap$10.64B$6.78B$5.80B$21.49BDividend YieldN/A1.21%5.72%3.50%P/E Ratio70.1025.8475.0429.84Price / Sales8.60194.87506.0368.89Price / Cash94.4822.1825.8118.13Price / Book8.794.9413.424.65Net Income$14.01M$176.38M$3.29B$999.94M7 Day Performance-8.31%4.58%0.09%1.08%1 Month Performance4.18%7.06%4.56%4.53%1 Year Performance40.54%10.95%74.87%14.39% Penumbra Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PENPenumbra4.7244 of 5 stars$263.58-3.4%$302.93+14.9%+41.0%$10.64B$1.19B70.104,500Positive NewsLNTHLantheus4.539 of 5 stars$53.63-2.0%$91.60+70.8%-51.0%$3.65B$1.53B14.26700Trending NewsAnalyst ForecastITGRInteger4.0808 of 5 stars$106.01-0.9%$140.25+32.3%-21.0%$3.71B$1.72B46.7011,000Positive NewsGEHCGE HealthCare Technologies4.2408 of 5 stars$78.16+3.2%$88.55+13.3%-10.5%$34.58B$19.97B16.0253,000Positive NewsPHGKoninklijke Philips3.3373 of 5 stars$27.88-0.2%N/A-8.4%$26.89B$17.86B146.7166,678Short Interest ↓ZBHZimmer Biomet4.8002 of 5 stars$104.74-0.9%$111.00+6.0%-5.0%$20.75B$7.68B25.4817,000Positive NewsSNNSmith & Nephew SNATS3.1377 of 5 stars$38.38+0.8%$36.00-6.2%+18.6%$16.81B$5.81B17.7717,349SOLVSolventum2.1461 of 5 stars$74.62+2.6%$85.75+14.9%+4.6%$12.94B$8.25B34.5522,000Positive NewsAnalyst ForecastSTVNStevanato GroupN/A€25.53+5.7%N/A+36.0%€7.73B€1.15B47.285,521Gap UpIRTCiRhythm Technologies1.2211 of 5 stars$187.07+3.3%$163.82-12.4%+129.9%$6.01B$591.84M-63.852,000Positive NewsBLCOBausch + Lomb2.0722 of 5 stars$15.50+3.3%$15.56+0.3%-2.1%$5.49B$4.89B-19.8813,500 Related Companies and Tools Related Companies Lantheus Competitors Integer Competitors GE HealthCare Technologies Competitors Koninklijke Philips Competitors Zimmer Biomet Competitors Smith & Nephew SNATS Competitors Solventum Competitors Stevanato Group Competitors iRhythm Technologies Competitors Bausch + Lomb Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PEN) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Penumbra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Penumbra With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
